Tarsus Pharmaceuticals, Inc. TARS Common stock, capital shares reserved for future issuance
Common stock, capital shares reserved for future issuance at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance?
- Tarsus Pharmaceuticals, Inc. (TARS) reported common stock, capital shares reserved for future issuance of $19.53M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance increased by 6.0% year-over-year, from $18.42M to $19.53M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance has grown at a 9.7% compound annual growth rate (CAGR), from $11.25M to $17.87M.